目的探讨白癜风的发生与程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)抑制剂治疗临床获益之间的关系,为临床安全用药和不良反应监测提供参考。方法分析1例肺腺癌患者应用信迪利单抗致白癜风病例,并检索PubMed、Web of Science、中国...目的探讨白癜风的发生与程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)抑制剂治疗临床获益之间的关系,为临床安全用药和不良反应监测提供参考。方法分析1例肺腺癌患者应用信迪利单抗致白癜风病例,并检索PubMed、Web of Science、中国知网全文数据库中自2000年1月1日至2024年9月1日PD-1/PD-L1抑制剂引起皮肤白癜风的报道进行讨论。结果本例患者在使用PD-1抑制剂33个月后发生白癜风。结合患者临床表现和用药时间的相关性,考虑白癜风很可能由信迪利单抗引起。经文献分析,纳入分析的患者共20例,首次使用PD-1/PD-L1抑制剂至发生白癜风最短时间为免疫治疗第1个月后,最长是第20个月后,15例出现在免疫治疗的3~8个月。结论临床应用PD-1/PD-L1抑制剂要关注发生白癜风的风险,白癜风的发生可能与免疫治疗预后良好密切相关。展开更多
Objective To investigate the expression and regulation of programmed cell death protein 1(PD1),B lymphocyte and T lymphocyte attenuator(BTLA)in peripheral blood of patients with non-small cell lung cancer(NSCLC);to ex...Objective To investigate the expression and regulation of programmed cell death protein 1(PD1),B lymphocyte and T lymphocyte attenuator(BTLA)in peripheral blood of patients with non-small cell lung cancer(NSCLC);to examine the correlation of the mRNA levels between PD and BTLA in NSCLC.Methods Flow cytometry was used to detect the expression of PD1 and BTLA on the surfaces of CD8^+T cells andγδ+T cells in the peripheral blood samples collected from 32 in-patients with stage IV NSCLC and 30 healthy individuals.We compared the expression of PD1 and BTLA on the surfaces ofγδ+T cells in the NSCLC patients with bone metastasis before and after the treatment of zoledronic acid.The correlations of PD1 and BTLA,as well as their ligands were analyzed using Pearson correlation analysis with the cBioPortal data platform.Results The frequency of PD1 on the surfaces of CD8^+T cells was significantly higher than that of theγδT cells in both healthy controls(t=2.324,P=0.024)and NSCLC patients(t=2.498,P=0.015).The frequency of PD1 on CD8^+T cells,rather than onγδ+T cells,was significantly upregulated in advanced NSCLC patients compared with that in healthy controls(t=4.829,P<0.001).The PD1+BTLA+γδT cells of the healthy controls were significantly lower than that of the NSCLC patients(t=2.422,P=0.0185).No differences in percentage of PD1+γδ+and BTLA+γδ+T cells were observed in 7 NSCLC patients with bone metastasis before and after zoledronic acid treatment.PD1 was positively correlated with BTLA in both lung adenocarcinoma(r=0.54;P<0.05)and lung squamous cell carcinoma(r=0.78;P<0.05).Conclusions The upregulation of co-inhibitory molecules occurs on the surfaces of both CD8^+T cells andγδT cells in advanced NSCLC,suggesting that these molecules were involved in regulating the inactivation of CD8^+T cells andγδ+T cells,immune escape and tumor invasion.展开更多
文摘目的探讨白癜风的发生与程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)抑制剂治疗临床获益之间的关系,为临床安全用药和不良反应监测提供参考。方法分析1例肺腺癌患者应用信迪利单抗致白癜风病例,并检索PubMed、Web of Science、中国知网全文数据库中自2000年1月1日至2024年9月1日PD-1/PD-L1抑制剂引起皮肤白癜风的报道进行讨论。结果本例患者在使用PD-1抑制剂33个月后发生白癜风。结合患者临床表现和用药时间的相关性,考虑白癜风很可能由信迪利单抗引起。经文献分析,纳入分析的患者共20例,首次使用PD-1/PD-L1抑制剂至发生白癜风最短时间为免疫治疗第1个月后,最长是第20个月后,15例出现在免疫治疗的3~8个月。结论临床应用PD-1/PD-L1抑制剂要关注发生白癜风的风险,白癜风的发生可能与免疫治疗预后良好密切相关。
基金Fund supported by the Healthcare Technology Plan of Zhejiang Provincial Health Bureau(No.2016KYB292)the Technology Plan of Science and Technology Bureau of Jiaxing,Zhejiang province(No.2016AY23054)~~
文摘Objective To investigate the expression and regulation of programmed cell death protein 1(PD1),B lymphocyte and T lymphocyte attenuator(BTLA)in peripheral blood of patients with non-small cell lung cancer(NSCLC);to examine the correlation of the mRNA levels between PD and BTLA in NSCLC.Methods Flow cytometry was used to detect the expression of PD1 and BTLA on the surfaces of CD8^+T cells andγδ+T cells in the peripheral blood samples collected from 32 in-patients with stage IV NSCLC and 30 healthy individuals.We compared the expression of PD1 and BTLA on the surfaces ofγδ+T cells in the NSCLC patients with bone metastasis before and after the treatment of zoledronic acid.The correlations of PD1 and BTLA,as well as their ligands were analyzed using Pearson correlation analysis with the cBioPortal data platform.Results The frequency of PD1 on the surfaces of CD8^+T cells was significantly higher than that of theγδT cells in both healthy controls(t=2.324,P=0.024)and NSCLC patients(t=2.498,P=0.015).The frequency of PD1 on CD8^+T cells,rather than onγδ+T cells,was significantly upregulated in advanced NSCLC patients compared with that in healthy controls(t=4.829,P<0.001).The PD1+BTLA+γδT cells of the healthy controls were significantly lower than that of the NSCLC patients(t=2.422,P=0.0185).No differences in percentage of PD1+γδ+and BTLA+γδ+T cells were observed in 7 NSCLC patients with bone metastasis before and after zoledronic acid treatment.PD1 was positively correlated with BTLA in both lung adenocarcinoma(r=0.54;P<0.05)and lung squamous cell carcinoma(r=0.78;P<0.05).Conclusions The upregulation of co-inhibitory molecules occurs on the surfaces of both CD8^+T cells andγδT cells in advanced NSCLC,suggesting that these molecules were involved in regulating the inactivation of CD8^+T cells andγδ+T cells,immune escape and tumor invasion.
